HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia.

Abstract
Gamma-secretase inhibitors (GSIs) block the activation of the oncogenic protein Notch homolog-1 (NOTCH1) in T cell acute lymphoblastic leukemia (T-ALL). However, limited antileukemic cytotoxicity and severe gastrointestinal toxicity have restricted the clinical application of these targeted drugs. Here we show that combination therapy with GSIs plus glucocorticoids can improve the antileukemic effects of GSIs and reduce their gut toxicity in vivo. Inhibition of NOTCH1 signaling in glucocorticoid-resistant T-ALL restored glucocorticoid receptor autoupregulation and induced apoptotic cell death through induction of the gene encoding BCL-2-like apoptosis initiator-11 (BCL2L11). GSI treatment resulted in cell cycle arrest and accumulation of goblet cells in the gut mediated by upregulation of the gene encoding the transcription factor Krüppel-like factor-4 (Klf4), a negative regulator of the cell cycle required for goblet cell differentiation. In contrast, glucocorticoid treatment induced transcriptional upregulation of cyclin D2 (Ccnd2) and protected mice from developing the intestinal goblet cell metaplasia typically induced by inhibition of NOTCH signaling with GSIs. These results support a role for glucocorticoids plus GSIs in the treatment of glucocorticoid-resistant T-ALL.
AuthorsPedro J Real, Valeria Tosello, Teresa Palomero, Mireia Castillo, Eva Hernando, Elisa de Stanchina, Maria Luisa Sulis, Kelly Barnes, Catherine Sawai, Irene Homminga, Jules Meijerink, Iannis Aifantis, Giuseppe Basso, Carlos Cordon-Cardo, Walden Ai, Adolfo Ferrando
JournalNature medicine (Nat Med) Vol. 15 Issue 1 Pg. 50-8 (Jan 2009) ISSN: 1546-170X [Electronic] United States
PMID19098907 (Publication Type: Evaluation Study, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Apoptosis Regulatory Proteins
  • BCL2L11 protein, human
  • Bcl-2-Like Protein 11
  • Bcl2l11 protein, mouse
  • Ccnd2 protein, mouse
  • Cyclin D2
  • Cyclins
  • Enzyme Inhibitors
  • Glucocorticoids
  • KLF4 protein, human
  • Klf4 protein, mouse
  • Kruppel-Like Factor 4
  • Membrane Proteins
  • NR3C1 protein, human
  • Proto-Oncogene Proteins
  • Receptor, Notch1
  • Receptors, Glucocorticoid
  • Dexamethasone
  • Amyloid Precursor Protein Secretases
Topics
  • Amyloid Precursor Protein Secretases (antagonists & inhibitors)
  • Animals
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Apoptosis Regulatory Proteins (genetics, physiology)
  • Bcl-2-Like Protein 11
  • Cyclin D2
  • Cyclins (genetics)
  • Dexamethasone (administration & dosage, therapeutic use)
  • Drug Resistance, Neoplasm (drug effects)
  • Enzyme Inhibitors (administration & dosage, pharmacology)
  • Female
  • Gene Expression Regulation, Leukemic (drug effects)
  • Glucocorticoids (administration & dosage, therapeutic use)
  • Homeostasis (drug effects, physiology)
  • Kruppel-Like Factor 4
  • Membrane Proteins (genetics, physiology)
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Mice, SCID
  • Models, Biological
  • Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (drug therapy, genetics, metabolism)
  • Proto-Oncogene Proteins (genetics, physiology)
  • Receptor, Notch1 (antagonists & inhibitors, genetics, physiology)
  • Receptors, Glucocorticoid (genetics, metabolism, physiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: